Wall Street brokerages forecast that Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) will report earnings of ($1.10) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Alder BioPharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.54) and the highest estimate coming in at ($0.93). Alder BioPharmaceuticals reported earnings per share of ($0.97) during the same quarter last year, which would suggest a negative year-over-year growth rate of 13.4%. The company is expected to issue its next quarterly earnings report on Thursday, February 22nd.
On average, analysts expect that Alder BioPharmaceuticals will report full-year earnings of ($5.36) per share for the current fiscal year, with EPS estimates ranging from ($5.94) to ($5.08). For the next year, analysts anticipate that the firm will report earnings of ($3.75) per share, with EPS estimates ranging from ($5.42) to ($2.83). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Alder BioPharmaceuticals.
Alder BioPharmaceuticals (NASDAQ:ALDR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($1.21) by $0.29. During the same quarter in the previous year, the company earned ($0.70) earnings per share.
ALDR has been the topic of several analyst reports. ValuEngine raised shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 30th. Mizuho reissued a “buy” rating and issued a $32.00 target price on shares of Alder BioPharmaceuticals in a research report on Wednesday. Cowen and Company started coverage on shares of Alder BioPharmaceuticals in a research report on Tuesday, September 26th. They issued an “outperform” rating and a $20.00 target price on the stock. Royal Bank of Canada started coverage on shares of Alder BioPharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $17.00 price objective on the stock. Finally, Canaccord Genuity started coverage on shares of Alder BioPharmaceuticals in a research report on Thursday, October 26th. They set a “buy” rating and a $20.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Alder BioPharmaceuticals has a consensus rating of “Buy” and a consensus price target of $28.07.
In other Alder BioPharmaceuticals news, insider Mark James Litton sold 16,520 shares of Alder BioPharmaceuticals stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $12.33, for a total value of $203,691.60. Following the completion of the sale, the insider now directly owns 116,452 shares in the company, valued at $1,435,853.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.60% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Alder BioPharmaceuticals by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,626,573 shares of the biopharmaceutical company’s stock valued at $41,525,000 after acquiring an additional 187,871 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Alder BioPharmaceuticals in the second quarter valued at approximately $36,956,000. Redmile Group LLC lifted its stake in Alder BioPharmaceuticals by 16.4% in the second quarter. Redmile Group LLC now owns 2,223,811 shares of the biopharmaceutical company’s stock valued at $25,463,000 after acquiring an additional 313,925 shares during the last quarter. State Street Corp lifted its stake in Alder BioPharmaceuticals by 9.4% in the second quarter. State Street Corp now owns 1,944,755 shares of the biopharmaceutical company’s stock valued at $22,267,000 after acquiring an additional 167,642 shares during the last quarter. Finally, BB Biotech AG lifted its stake in Alder BioPharmaceuticals by 15.2% in the second quarter. BB Biotech AG now owns 1,941,008 shares of the biopharmaceutical company’s stock valued at $22,225,000 after acquiring an additional 255,858 shares during the last quarter. Hedge funds and other institutional investors own 78.57% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/11/12/zacks-analysts-expect-alder-biopharmaceuticals-inc-aldr-will-post-earnings-of-1-10-per-share.html.
Alder BioPharmaceuticals (NASDAQ:ALDR) opened at $11.15 on Friday. Alder BioPharmaceuticals has a 1 year low of $8.60 and a 1 year high of $34.30.
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Get a free copy of the Zacks research report on Alder BioPharmaceuticals (ALDR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.